Skip to main content

BioVie to Present at 2021 B. Riley Securities’ Neuroscience Conference

Written by Customer Service on . Posted in Public Companies.

SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurological and neuro-degenerative disorders and certain cancers, today announced the participation of its President and Chief Executive Officer Cuong Do at the 2021 B. Riley Securities’ Neuroscience Conference. Mr. Do is scheduled to present on Wednesday, April 28 at 3:00 PM Eastern Time and will discuss BioVie’s pending acquisition of NeurMedix’s assets and plans going forward for Alzheimer’s and Parkinson’s.

BioVie Presentation Details

Date: Wednesday, April 28, 2021
Time: 3:00 PM Eastern Time

A live webcast of BioVie’s presentation will be available [Here] and a replay will be available for a period of one year.

Also, on Thursday, April 29, 2021 at 8:00 AM, B. Riley will host a KOL Discussion where the role of neuroinflammation in Alzheimer’s will be discussed titled: Forgetting the “Past” So that We Can Remember the “Now”: Deep Dive on Next-Gen, Mid-Stage Candidates for Alzheimer’s Disease. Dr. Alan A. Mazurek, Icahn School of Medicine at Mount Sinai; Dr. Martin J. Sadowski, NYU School of Medicine. This scientific discussion is relevant to the Company’s promising new drug candidate, NE3107, that is designed to reduce neuroinflammation in Alzheimer’s disease.

About BioVie, Inc.

BioVie Inc. (“BioVie”) is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurological and neuro-degenerative disorders and certain cancers. The company’s lead clinical drug candidate to be acquired from NeurMedix, NE3107, has successfully completed 11 pre-clinical, and 6 Phase 1, Phase 1/2, and Phase 2 clinical studies in various inflammatory diseases indicating its broad potential to inhibit inflammatory cascade without evidence of immunosuppression. In addition to Alzheimer’s Disease, BioVie plans to enter clinical trials for the treatment of Parkinson’s Disease and several oncological indications. The Company is focused on diseases with significant unmet medical needs and commercial potential in order to expedite FDA review, minimize capital requirements and optimize shareholder value.

BioVie is also developing BIV201 (continuous infusion terlipressin) an Orphan drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis, and future development opportunities include hepatorenal syndrome (HRS) and other life-threatening complications. The Company recently initiated patient screening in its second US Phase 2 clinical trial, and upon completion will commence a pivotal Phase 3 trial shortly thereafter. The trial design is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. For more information, visit http://www.biovieinc.com/.

CONTACTS:

INVESTOR RELATIONS:
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.